Matteo Clavarezza

1.9k total citations
46 papers, 629 citations indexed

About

Matteo Clavarezza is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matteo Clavarezza has authored 46 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 21 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matteo Clavarezza's work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (13 papers) and Colorectal Cancer Treatments and Studies (12 papers). Matteo Clavarezza is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (13 papers) and Colorectal Cancer Treatments and Studies (12 papers). Matteo Clavarezza collaborates with scholars based in Italy, United Kingdom and United States. Matteo Clavarezza's co-authors include Marco Venturini, Lucia Del Mastro, Matteo Puntoni, Andrea DeCensi, Laura Paleari, M. Venturini, Claudia Bighin, Filippo Montemurro, Antonio Durando and Giorgio Valabrega and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Matteo Clavarezza

45 papers receiving 615 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matteo Clavarezza Italy 13 405 158 135 119 111 46 629
L. Schwartzberg United States 14 376 0.9× 85 0.5× 106 0.8× 48 0.4× 117 1.1× 61 640
Ana Herrero Spain 14 217 0.5× 137 0.9× 125 0.9× 31 0.3× 112 1.0× 41 591
Rubina Qamar United States 12 479 1.2× 210 1.3× 239 1.8× 83 0.7× 203 1.8× 21 908
S. Loibl Germany 10 254 0.6× 96 0.6× 123 0.9× 62 0.5× 93 0.8× 30 516
Irene De Santo Italy 9 394 1.0× 213 1.3× 342 2.5× 44 0.4× 169 1.5× 13 692
David Edward Lebwohl United States 8 503 1.2× 158 1.0× 117 0.9× 19 0.2× 110 1.0× 11 686
Barbara Radecka Poland 12 448 1.1× 134 0.8× 297 2.2× 74 0.6× 115 1.0× 59 639
Volker Moebus Germany 15 393 1.0× 224 1.4× 97 0.7× 33 0.3× 164 1.5× 52 705
P Bastit France 12 288 0.7× 209 1.3× 94 0.7× 47 0.4× 133 1.2× 29 541
J. F. R. Robertson United Kingdom 14 313 0.8× 138 0.9× 146 1.1× 62 0.5× 175 1.6× 29 666

Countries citing papers authored by Matteo Clavarezza

Since Specialization
Citations

This map shows the geographic impact of Matteo Clavarezza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Clavarezza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Clavarezza more than expected).

Fields of papers citing papers by Matteo Clavarezza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matteo Clavarezza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Clavarezza. The network helps show where Matteo Clavarezza may publish in the future.

Co-authorship network of co-authors of Matteo Clavarezza

This figure shows the co-authorship network connecting the top 25 collaborators of Matteo Clavarezza. A scholar is included among the top collaborators of Matteo Clavarezza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matteo Clavarezza. Matteo Clavarezza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clavarezza, Matteo, Luca Foppiani, Giampaola Pesce, et al.. (2023). Drug-induced thrombocytopenia in a patient with colorectal cancer: A case report. Oncology Letters. 26(3). 398–398. 1 indexed citations
2.
Clavarezza, Matteo, et al.. (2023). Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report. Cancer Chemotherapy and Pharmacology. 91(5). 435–439. 1 indexed citations
3.
Fucà, Giovanni, Alessandra Raimondi, Michele Prisciandaro, et al.. (2022). Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. The Oncologist. 27(1). e29–e36. 5 indexed citations
4.
Raimondi, Alessandra, Giovanni Fucà, Alberto Giovanni Leone, et al.. (2021). Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ESMO Open. 6(5). 100246–100246. 10 indexed citations
5.
6.
Brandes, Alba A., Gaetano Finocchiaro, Vittorina Zagonel, et al.. (2016). AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-Oncology. 18(9). 1304–1312. 61 indexed citations
7.
Puntoni, Matteo, Marco Piccininno, Arnoldo Piccardo, et al.. (2016). Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. Translational Oncology. 9(6). 600–605. 9 indexed citations
8.
Clavarezza, Matteo, Matteo Puntoni, Alessandra Gennari, et al.. (2016). Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials. Clinical Cancer Research. 22(18). 4594–4603. 27 indexed citations
9.
Paleari, Laura, Matteo Puntoni, Matteo Clavarezza, et al.. (2015). PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Annals of Oncology. 26. vi36–vi36. 3 indexed citations
10.
11.
12.
13.
Clavarezza, Matteo, Monica Turazza, Enrico Aitini, et al.. (2013). Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. The Breast. 22(4). 470–475. 11 indexed citations
14.
Gori, Stefania, Matteo Clavarezza, Salvatore Siena, et al.. (2012). Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer. 12(1). 158–158. 12 indexed citations
15.
Clavarezza, Matteo, Giorgio Mustacchi, Andrea Casadei‐Gardini, et al.. (2012). Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer. 12(1). 216–216. 6 indexed citations
16.
Lunardi, Gianluigi, Patrizia Piccioli, Paolo Bruzzi, et al.. (2012). Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. Breast Cancer Research and Treatment. 137(1). 167–174. 14 indexed citations
17.
Montemurro, Filippo, Stefania Redana, Giuseppe Viale, et al.. (2008). Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. Clinical Breast Cancer. 8(5). 436–442. 23 indexed citations
18.
Mastro, Lucia Del, Matteo Clavarezza, & Marco Venturini. (2007). Reducing the risk of distant metastases in breast cancer patients: Role of aromatase inhibitors. Cancer Treatment Reviews. 33(8). 681–687. 11 indexed citations
19.
Clavarezza, Matteo, Lucia Del Mastro, & M. Venturini. (2006). Taxane-containing chemotherapy in the treatment of early breast cancer patients. Annals of Oncology. 17. vii22–vii26. 9 indexed citations
20.
Mastro, Lucia Del, Luca Boni, M. R. Sertoli, et al.. (2005). Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Annals of Oncology. 17(1). 74–78. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Schwartzberg Breakdown of academic impact, for papers by Ana Herrero Breakdown of academic impact, for papers by Rubina Qamar Breakdown of academic impact, for papers by S. Loibl Breakdown of academic impact, for papers by Irene De Santo Breakdown of academic impact, for papers by David Edward Lebwohl Breakdown of academic impact, for papers by Barbara Radecka Breakdown of academic impact, for papers by Volker Moebus Breakdown of academic impact, for papers by P Bastit Breakdown of academic impact, for papers by J. F. R. Robertson
Rankless by CCL
2026